Kindred Biosciences (KIN) Insider Richard Chin Sells 2,400 Shares

Kindred Biosciences (NASDAQ:KIN) insider Richard Chin sold 2,400 shares of the business’s stock in a transaction on Friday, May 18th. The shares were sold at an average price of $10.00, for a total value of $24,000.00. Following the transaction, the insider now owns 2,241,741 shares of the company’s stock, valued at approximately $22,417,410. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Richard Chin also recently made the following trade(s):

  • On Monday, May 7th, Richard Chin sold 1,730 shares of Kindred Biosciences stock. The shares were sold at an average price of $10.01, for a total value of $17,317.30.
  • On Wednesday, May 9th, Richard Chin sold 1,930 shares of Kindred Biosciences stock. The shares were sold at an average price of $10.01, for a total value of $19,319.30.
  • On Tuesday, May 1st, Richard Chin sold 20,000 shares of Kindred Biosciences stock. The shares were sold at an average price of $9.05, for a total value of $181,000.00.
  • On Monday, April 2nd, Richard Chin sold 20,000 shares of Kindred Biosciences stock. The shares were sold at an average price of $8.39, for a total value of $167,800.00.

Shares of KIN stock traded down $0.40 during mid-day trading on Friday, hitting $9.55. The stock had a trading volume of 140,137 shares, compared to its average volume of 95,473. Kindred Biosciences has a 12-month low of $6.55 and a 12-month high of $10.15. The stock has a market capitalization of $279.21 million, a price-to-earnings ratio of -7.76 and a beta of 0.08.

Kindred Biosciences (NASDAQ:KIN) last issued its earnings results on Tuesday, May 8th. The biopharmaceutical company reported ($0.36) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.36). analysts forecast that Kindred Biosciences will post -1.53 EPS for the current fiscal year.

Several equities research analysts have weighed in on KIN shares. Zacks Investment Research cut Kindred Biosciences from a “hold” rating to a “sell” rating in a report on Saturday, May 12th. HC Wainwright upped their target price on Kindred Biosciences to $12.00 and gave the stock a “buy” rating in a report on Wednesday, May 9th. ValuEngine upgraded Kindred Biosciences from a “hold” rating to a “buy” rating in a report on Tuesday, April 17th. Finally, BidaskClub upgraded Kindred Biosciences from a “hold” rating to a “buy” rating in a report on Saturday, April 14th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $10.35.

Several institutional investors and hedge funds have recently added to or reduced their stakes in KIN. Citigroup Inc. raised its position in shares of Kindred Biosciences by 2,575.3% in the 1st quarter. Citigroup Inc. now owns 31,007 shares of the biopharmaceutical company’s stock worth $268,000 after acquiring an additional 29,848 shares in the last quarter. Schwab Charles Investment Management Inc. raised its position in shares of Kindred Biosciences by 18.6% in the 4th quarter. Schwab Charles Investment Management Inc. now owns 42,100 shares of the biopharmaceutical company’s stock worth $398,000 after acquiring an additional 6,600 shares in the last quarter. Bank of New York Mellon Corp raised its position in shares of Kindred Biosciences by 12.1% in the 4th quarter. Bank of New York Mellon Corp now owns 83,543 shares of the biopharmaceutical company’s stock worth $789,000 after acquiring an additional 8,995 shares in the last quarter. B. Riley Financial Inc. bought a new position in shares of Kindred Biosciences in the 1st quarter worth $1,120,000. Finally, New York State Common Retirement Fund raised its position in shares of Kindred Biosciences by 6.2% in the 1st quarter. New York State Common Retirement Fund now owns 243,249 shares of the biopharmaceutical company’s stock worth $2,104,000 after acquiring an additional 14,285 shares in the last quarter. 64.32% of the stock is owned by hedge funds and other institutional investors.

About Kindred Biosciences

Kindred Biosciences, Inc, a biopharmaceutical company, focuses on the development of therapies for pets. The company's product pipeline includes small molecules and biologics for a range of indications in dogs, cats, and horses. Its lead product candidates comprise Zimeta, a dipyrone injection for the control of pyrexia (fever) in horses; and Mirataz, a mirtazapine transdermal ointment for the management of weight loss in cats.

Insider Buying and Selling by Quarter for Kindred Biosciences (NASDAQ:KIN)

Receive News & Ratings for Kindred Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kindred Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply